NEFL and amyotrophic lateral sclerosis: However, while the FDA has considered the pharmacodynamic response in NfL in regulatory decisions for tofersen in the clinically manifest SOD1 ALS population,15,112 the agency also has underscored the unique nature of this particular circumstance and discouraged investigators from inferring that future approval decisions will follow the same path.